These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 348315)

  • 1. Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.
    Gralla RJ; Currie VE; Wittes RE; Golbey RB; Young CW
    Cancer Treat Rep; 1978 Mar; 62(3):451-2. PubMed ID: 348315
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma.
    Carroll DS; Kemeny NE; Gralla RJ
    Cancer Treat Rep; 1979 Jan; 63(1):139-40. PubMed ID: 369686
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial of pyrazofurin in advanced head and neck cancer.
    Cheng E; Currie V; Wittes RE
    Cancer Treat Rep; 1979; 63(11-12):2047-8. PubMed ID: 526937
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
    Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
    Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study on DON in patients with previously treated advanced lung cancer.
    Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
    Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of pyrazofurin in advanced colorectal carcinoma.
    Creagan ET; Rubin J; Moertel CG; Schutt AJ; O'connell MJ; Hahn RG; Reitemeir RJ; Frytak S
    Cancer Treat Rep; 1977; 61(3):491-3. PubMed ID: 872147
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I study of pyrazofurin in refractory acute myelogenous leukemia.
    Vogler WR; Trulock PD
    Cancer Treat Rep; 1978 Oct; 62(10):1569-71. PubMed ID: 152146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of pyrazofurin in malignant melanoma.
    Budman D; Currie V; Wittes R
    Cancer Treat Rep; 1977 Dec; 61(9):1733-4. PubMed ID: 340040
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of advanced non-small cell lung cancer with bisantrene.
    Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
    Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
    Nichols WC; Kvols LK; Ingle JN; Edmonson JH; Ahmann DL; Rubin J; O'Connell MJ
    Cancer Treat Rep; 1978 May; 62(5):837-9. PubMed ID: 657166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of tiazofurin in recurrent squamous cell carcinoma of the head and neck.
    Dimery IW; Neidhart JA; McCarthy K; Krakoff IH; Hong WK
    Cancer Treat Rep; 1987 Apr; 71(4):425-6. PubMed ID: 3548960
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II evaluation of pyrazofurin in patients with metastatic sarcoma.
    Gralla RJ; Sordillo PP; Magill GB
    Cancer Treat Rep; 1978 Oct; 62(10):1573-4. PubMed ID: 361228
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical trial of weekly pyrazofurin.
    Cummings FJ; Stoller RG; Calabresi P
    Cancer Treat Rep; 1979 Aug; 63(8):1363-5. PubMed ID: 157807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of acivicin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.
    Booth BW; Korzun AH; Weiss RB; Ellison RR; Budman D; Khojasteh A; Wood W
    Cancer Treat Rep; 1986 Oct; 70(10):1247-8. PubMed ID: 3530455
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of aclarubicin in epidermoid carcinoma of the head and neck.
    Carugati AA; Olivari AJ; Campos DM; Pradier R; Woolley PV
    Cancer Treat Rep; 1986 Jun; 70(6):799-800. PubMed ID: 3524828
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II evaluation of bisantrene in patients with renal cell carcinoma.
    Myers JW; Von Hoff DD; Coltman CA; Kuhn JG; Van Echo D; Rivkin S; Pocelinko R
    Cancer Treat Rep; 1982 Oct; 66(10):1869-71. PubMed ID: 7127326
    [No Abstract]   [Full Text] [Related]  

  • 17. [Phase II study of KW2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with carcinoma of the lung and metastatic pulmonary tumor].
    Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Shibuya M; Shimabukuro Z
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):834-9. PubMed ID: 6882001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of AMSA in patients with metastatic lung cancer.
    Nichols WC; Eagan RT; Frytak S; Ingle JN; Creagan ET; Kvols LK
    Cancer Treat Rep; 1980; 64(12):1383-5. PubMed ID: 6894104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy.
    Lake-Lewin D; Myers J; Lee BJ; Young CW
    Cancer Treat Rep; 1979 Aug; 63(8):1403-4. PubMed ID: 476714
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
    Myers JW; Von Hoff DD; Clark GM; Coltman CA
    Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.